Display Single Record

FOI Request

Disclosure ID
FOI/02546
Request Date
July 6, 2018
Subject
Bisphosphonates
Description
  1. Does your Trust routinely provide bisphosphonates to postmenopausal women with primary breast cancer to reduce the risk of their cancer spreading to other parts of the body?
  2. If your Trust does routinely provide bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but is not providing them for all postmenopausal women, how is eligibility defined? For example, women at increased risk of recurrence.
  3. If your Trust does routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, which bisphosphonates do you prescribe?  For example, zoledronic acid, ibandronic acid, sodium clodronate.
  4. If your Trust does not routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, what are your reasons for not doing so?
Response
  1. Yes in adjuvant patients
  2. Eligibility is patients undergoing Adjuvant treatment
  3. Zolodrenic Acid
  4. N/A
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
Attachment 6
Attachment 7
Attachment 8
Attachment 9